Month: December 2020

20744-39-2, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 20744-39-2, name is Pyridazin-4-amine, introducing its new discovery.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson?s disease and Alzheimer?s disease

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.20744-39-2, you can also check out more blogs about20744-39-2

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N131 – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels. 141-30-0, In a patent£¬Which mentioned a new discovery about 141-30-0

Novel thioamide derivatives containing a pyridazine group

Novel pyridazine-containing thioamide derivatives of the formula STR1 wherein R1 is STR2 wherein A is hydrogen, methyl, phenyl or mercapto, and B is hydrogen or phenyl; R2 is hydrogen or methyl; R3 is hydrogen, methyl or phenyl; R4 is hydrogen or methyl; and n is zero or 1. The derivatives have outstanding gastric antisecretory activity.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 141-30-0, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 141-30-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1533 – PubChem

 

Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 19064-67-6, Name is 6-Chloro-3-hydroxypyridazine, molecular formula is C4H3ClN2O, 19064-67-6, In a Article, authors is O’Malley, Daniel P.£¬once mentioned of 19064-67-6

Discovery of Pyridazinone and Pyrazolo[1,5- a]pyridine Inhibitors of C-Terminal Src Kinase

C-terminal Src kinase (CSK) functions as a negative regulator of T cell activation through inhibitory phosphorylation of LCK, so inhibitors of CSK are of interest as potential immuno-oncology agents. Screening of an internal kinase inhibitor collection identified pyridazinone lead 1, and a series of modifications led to optimized compound 13. Compound 13 showed potent activity in biochemical and cellular assays in vitro and demonstrated the ability to increase T cell proliferation induced by T cell receptor signaling. Compound 13 gave extended exposure in mice upon oral dosing and produced a functional response (decrease in LCK phosphorylation) in mouse spleens at 6 h post dose.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.19064-67-6. In my other articles, you can also check out more blogs about 19064-67-6

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N763 – PubChem

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels. 66346-87-0. In a patent£¬Which mentioned a new discovery about 66346-87-0, molcular formula is C5H6ClN3, introducing its new discovery.

6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to the general formula (I) in which R2 represents an aryl group optionally substituted with one or more halogen atoms or C1-6-alkyl, C1-6-alkyloxy, C1-6-alkylthio, C1-6-fluoroalkyl, C1-6-fluoroalkyloxy and ?CN groups or R2 represents a group chosen from C1-6-alkyl, C1-6-fluoroalkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-6-alkyl groups; A represents a C1-7-alkylene group; B represents a C1-7-alkylene group; L represents either a nitrogen atom optionally substituted with an Rc or Rd group, or a carbon atom substituted with an Re1 group and an Rd group or two Re2 groups; the carbon atoms of A and of B being optionally substituted with one or more Rf groups, which may be identical to or different from one another. Preparation process and therapeutic use.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, 66346-87-0, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 66346-87-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1086 – PubChem

 

141-30-0, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 141-30-0

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

This invention relates to novel sulfonyl pyridazinone compounds useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.

141-30-0, If you are hungry for even more, make sure to check my other article about 141-30-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1555 – PubChem

 

35857-89-7, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 35857-89-7

Alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as alpha2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the alpha2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

35857-89-7, Interested yet? Read on for other articles about 35857-89-7!

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N873 – PubChem

 

13327-27-0, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 13327-27-0

BROMODOMAIN INHIBITORS

Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

13327-27-0, If you are hungry for even more, make sure to check my other article about 13327-27-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N282 – PubChem

 

286946-24-5, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 286946-24-5

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, Land n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

286946-24-5, Interested yet? Read on for other articles about 286946-24-5!

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2895 – PubChem

 

932-22-9, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 932-22-9, name is 4,5-Dichloro-3(2H)-pyridazinone, introducing its new discovery.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.932-22-9, you can also check out more blogs about932-22-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2247 – PubChem

 

141-30-0, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 141-30-0, Name is 3,6-Dichloropyridazine, molecular formula is C4H2Cl2N2. In a Article, authors is Perry, Benjamin£¬once mentioned of 141-30-0

Optimization of a series of multi-isoform PI3 kinase inhibitors

Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.141-30-0. In my other articles, you can also check out more blogs about 141-30-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1857 – PubChem